At a glance
ClinicalIndex Comparison Record- ✓Confirmed HCC by histopathology, cytology, or imaging with cirrhosis
- ✓Oligoprogression after first-line PD-1 therapy
- ✓Stable disease for at least 3 months after first-line PD-1 therapy
- ✓≤5 lesions in ≤3 organs
- ✕Fibrous lamina, sarcomatoid, or cholangiocarcinoma histology
- ✕History of hepatic encephalopathy or liver transplantation
- ✕Symptomatic pleural effusion, ascites, or pericardial effusion requiring drainage
- ✕Untreated hepatitis: HBV DNA >2000 IU/ml or >10^4 copy/ml, HCV RNA >10^3 copy/ml, or HBsAg/anti-HCV positive
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06870942Phase 2RecruitingUpdate OverdueUpdated 15mo ago · Completion was 19mo agoEfficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy: A Phase II Clinical Study
In Brief
A Phase 2 clinical trial evaluating Maintenance first-line treatment plus radiation therapy for HCC - Hepatocellular Carcinoma and Radiotherapy. Currently recruiting, targeting 35 participants across 1 site.
Signals
Detailed Summary
Immune checkpoint inhibitors (ICIs) have significantly improved the survival outcomes of HCC patients. However, a considerable proportion of patients eventually experience disease progression due to the development of resistance. Among these, oligoprogression is a common manifestation, occurring in 10-55.3% of advanced cancer patients. Local therapy, especially radiotherapy (RT), has been increasingly considered in the setting of oligoprogression to overcome ICIs resistance and delay the need to change systemic therapy. Therefore, this study aimed to explore the efficacy and safety of RT in oligoprogressive HCC following first-line PD-1 therapy.
Study Details
Timeline
Interventions
Maintenance first-line treatment plus radiation therapy